*Both authors contributed equally.
Budesonide in previously untreated autoimmune hepatitis
Article first published online: 30 JUN 2005
Volume 25, Issue 5, pages 927–934, October 2005
How to Cite
Wiegand, J., Schüler, A., Kanzler, S., Lohse, A., Beuers, U., Kreisel, W., Spengler, U., Koletzko, S., Jansen, P. L. M., Hochhaus, G., Möllmann, H. W., Pröls, M. and Manns, M. P. (2005), Budesonide in previously untreated autoimmune hepatitis. Liver International, 25: 927–934. doi: 10.1111/j.1478-3231.2005.01122.x
- Issue published online: 14 JUL 2005
- Article first published online: 30 JUN 2005
- Received 16 September 2004, accepted 31 January 2005
- autoimmune hepatitis;
- treatment options
Abstract: Background: Autoimmune hepatitis (AIH) is a chronic liver disease that is effectively treated with immunosuppressive therapy. Predniso(lo)ne, often in combination with azathioprine, is the basic therapeutic option to induce remission. However, this regimen can cause numerous side effects. The aim of the present study was to evaluate budesonide as a treatment option in the induction of remission in patients with previously untreated AIH.
Methods: Between October 1998 and August 1999, 12 patients were treated with 3 mg budesonide thrice daily for 3 months in this open one-arm multicenter phase IIa study. Primary end point was induction of remission indicated by a drop of aspartate aminotransferase and alanine aminotransferase levels below two times the upper limit of normal.
Results: Seven of the 12 patients (58%) reached complete remission, three patients (25%) had a partial response. Thus, 10/12 individuals (83.3%) responded to therapy. Therapy was tolerated well in 10/12 cases (83.3%).
Conclusions: Budesonide monotherapy was effective in the induction of remission and well tolerated in treatment naïve patients with AIH. It should be further evaluated in prospective controlled trials and should be compared to predniso(lo)ne both in monotherapy and in combination with azathioprine.